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Abstract
There is emerging evidence to show that high levels of NEFA contribute to endothelial dysfunction and impaired insulin sensitivity. How-
ever, the impact of NEFA composition remains unclear. A total of ten healthy men consumed test drinks containing 50 g of palm stearin
(rich in SFA) or high-oleic sunflower oil (rich in MUFA) on separate occasions; a third day included no fat as a control. The fats were emul-
sified into chocolate drinks and given as a bolus (approximately 10 g fat) at baseline followed by smaller amounts (approximately 3 g fat)
every 30 min throughout the 6 h study day. An intravenous heparin infusion was initiated 2 h after the bolus, which resulted in a three- to
fourfold increase in circulating NEFA level from baseline. Mean arterial stiffness as measured by digital volume pulse was higher during the
consumption of SFA (P,0·001) but not MUFA (P¼0·089) compared with the control. Overall insulin and gastric inhibitory peptide
response was greater during the consumption of both fats compared with the control (P,0·001); there was a second insulin peak in
response to MUFA unlike SFA. Consumption of SFA resulted in higher levels of soluble intercellular adhesion molecule-1 (sI-CAM) at
330 min than that of MUFA or control (P#0·048). There was no effect of the test drinks on glucose, total nitrite, plasminogen activator
inhibitor-1 or endothelin-1 concentrations. The present study indicates a potential negative impact of elevated NEFA derived from the
consumption of SFA on arterial stiffness and sI-CAM levels. More studies are needed to fully investigate the impact of NEFA composition
on risk factors for CVD.
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Insulin-resistant states such as obesity and type 2 diabetes
(T2D) are characterised by metabolic anomalies such as
elevated plasma NEFA levels. Epidemiological studies have
shown that elevated plasma NEFA are associated with a
greater risk of developing impaired glucose tolerance(1) and
T2D(2). Experimental elevation of plasma NEFA using intra-
venous infusion of lipid and heparin also results in impaired
insulin-stimulated glucose uptake in skeletal muscle(3) and
endothelial dysfunction(4), both of which are key features of
T2D and obesity(5,6). There is mounting evidence to suggest
that the saturation of dietary fat can influence endothelial
function; for example, consumption of SFA during weight-
loss regimens has been shown to be negatively associated
with flow-mediated dilatation (FMD)(7). Levels of SFA in
serum have also been shown to be inversely correlated with
endothelial-dependent forearm blood flow(8,9). Findings
from chronic dietary studies comparing diets rich in SFA or
MUFA are mixed. Some short-term studies have found that a
SFA-rich diet impairs vascular reactivity compared with a
MUFA-rich diet(10) or a diet rich in both MUFA and PUFA(11).
However, an 8-month supplementation trial found no differ-
ence in endothelial-dependent or -independent vasodilation
measures between MUFA- or SFA-based oils(12). Similarly,
there are contrasting findings frompostprandial studies compar-
ing high-fat meals rich in either SFA or MUFA, with some studies
finding no differential effect on FMD(13,14) and one study report-
ing a negative impact of a MUFA-rich meal on FMD(15).
Dietary fat composition may affect endothelial function by
modulating insulin sensitivity since the endothelium is an
insulin-dependent tissue, and impaired endothelial function
is a key feature of T2D and other insulin-resistant states.
Although the impact of dietary fatty acid composition on insu-
lin sensitivity remains equivocal(16), one large randomised
controlled trial found a decrease in insulin sensitivity after
substitution of monounsaturated fat for saturated fat over a
12-week period when total fat consumed constituted less
than 37 % energy(17). Furthermore, the Atherosclerosis Risk
in Community Study found that the percentage of SFA in
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plasma cholesteryl esters and phospholipids was positively
associated with the development of diabetes(18).
Mechanisms that might mediate the variable effects of diet-
ary fat on insulin sensitivity and endothelial function include
potentially direct effects of fatty acids on insulin signalling
pathways in endothelial cells, as has been described for skel-
etal muscle(3). In addition, there are potentially indirect effects
of different fatty acids on insulin secretion. The possibility
that this might be mediated via an effect on the secretion of
incretin hormones (gastric inhibitory peptide (GIP) and
glucagon-like peptide-1 (GLP-1)) is of particular interest
given the emerging therapeutic role of GLP-1, in particular
in the treatment of T2D. Indeed, infusion of GLP-1 has been
shown to cause a marked increase in FMD in T2D patients
with stable coronary artery disease(19). Whether such benefits
in incretin secretion might be achieved by dietary changes is
unclear, but postprandial studies have indicated that consump-
tion of MUFA-rich meals induces a higher incretin response than
consumption of SFA-rich meals(20,21). Furthermore, Southern
European subjects whose habitual diets were rich in MUFA
have been shown to have fasting levels of insulin twofold
higher and fasting levels of GIP over fourfold higher than a
matched group of Northern European subjects(22).
In addition to effects on insulin secretion, fatty acids may
have a direct impact on the insulin signalling pathway, influen-
cing the balance between vasodilator and vasoconstrictor
responses. Insulin signalling through the phosphoinositide-3
kinase pathway regulates the production of the vasodilator
NO, an important regulator of vascular tone(23). However, an
alternative pathway of insulin signalling, the mitogen-activated
protein kinase pathway, can lead to the generation of the vaso-
constrictor endothelin-1 (ET-1), as well as cellular adhesion
molecules such as soluble intercellular adhesion molecule-1
(sI-CAM) and plasminogen activator inhibitor-1 (PAI-1).
Evidence from cell culture studies suggests that different fatty
acids may affect the balance of these two pathways, with
particularly adverse effects of SFA, which may have significance
for impaired endothelial function and atherosclerosis(24,25).
Previous experimental studies of acute NEFA elevation have
been unable to study variable effects of fatty acid composition
since they have mostly used intravenous lipid emulsions such
as Intralipid, which are rich in n-6 PUFA. The present study
aimed to investigate the effects of acute elevation of plasma
NEFA of different composition using a relatively new protocol
developed by Beysen et al.(26), which involves frequent
ingestion of fat administered orally rather than by intravenous
infusion. We have examined the effect of elevating NEFA
derived from consumption of SFA- and MUFA-rich drinks on
the levels of insulin and incretin hormones, as well as on cir-
culating measures of endothelial function (total nitrite (NOx ),
sI-CAM, ET-1 and PAI-1). In addition, we used digital volume
pulse to assess arterial stiffness as a further marker of endo-
thelial function.
Experimental methods
The present study was conducted according to the guidelines
laid down in the Declaration of Helsinki, and all procedures
involving human subjects were approved by the University
of Reading Ethics Committee. Written informed consent was
obtained from all subjects. The study was conducted in the
Hugh Sinclair Unit of Human Nutrition at the University of
Reading.
The method of elevating NEFA of specific types is based on
that by Beysen et al.(27). A drink mixture was prepared com-
prising 50 g of either palm stearin (SFA; 59 % 16 : 0, 28 %
18 : 1n-9, 6 % 18 : 2n-6, 5 % 18 : 0) or high-oleic sunflower oil
(MUFA; 81 % 18 : 1n-9, 10 % 18 : 2n-6, 4 % 16 : 0, 3 % 18 : 0),
30 g skimmed milk powder (Premier International Foods
Limited, Birmingham, UK), 15 g chocolate powder (The
Spanish Chocolate Company Limited, Leicester, UK) and
0·5 g monoacylglycerol emulsifier (Danisco, Copenhagen,
Denmark). Water was added to achieve a final weight of
320 g, and the mixture was blended for several minutes to
ensure emulsification. The test drinks were identical in protein
(11·5 g) and carbohydrate (28·1 g) content. The drinks were
divided into a main test drink of 62 g (approximately 10 g
fat, 5·4 g carbohydrate and 2·2 g protein) and twelve smaller
drinks of 21 g (approximately 3 g fat, 1·8 g carbohydrate and
0·75 g protein). Control drinks were prepared using the
same method but excluding the oils. All drinks were served
warm to enhance palatability.
Healthy men (n 10; Table 1) were recruited to take part in
three study days. All subjects were non-smokers of normal
body weight and were not suffering from hyperlipidaemia
or any endocrine disorder likely to affect lipid metabolism;
all showed normal lipid and standard clinical biochemistry
values on screening. Subjects attended the Unit on three
occasions separated by at least 1 week and were randomly
assigned to one of the test drinks on each day. For 24 h
before each study day, subjects were asked to refrain from
strenuous exercise and alcohol and were supplied with a
low-fat ready meal to be consumed in the evening. On each
study day, subjects arrived after an overnight fast, and an intra-
venous cannula was placed at the wrist of the non-dominant
arm. The main test drink was consumed at 0 min, with
the smaller drinks given every 30 min for a further 6 h.
At 120 min, a second cannula was inserted into the antecubital
vein in the non-dominant arm for the infusion of heparin.
A bolus of heparin (500 IU) was administered, followed by a
Table 1. Baseline characteristics of the ten male subjects
(Mean values and standard deviations)
Mean SD
Age (years) 24·8 7·2
Ht (m) 1·8 0·1
Wt (kg) 74·2 10·2
BMI (kg/m2) 22·5 2·4
Waist circumference (cm) 84·1 5·4
BP (mmHg)
Systolic 128 10
Diastolic 74 5
Fasting total cholesterol (mmol/l) 4·1 0·9
Fasting glucose (mmol/l) 5·5 0·6
Fasting TAG (mmol/l) 0·9 0·3
BP, blood pressure.
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continuous infusion of heparin (0·4 IU/kg body weight per
min) for the rest of the study day.
Stiffness index derived from digital volume pulse (SIDVP)
was measured four times during each study day using digital
volume pulse with a PulseTrace PCA 2 (Micro Medical Limited,
Kent, UK). SIDVP has been shown to be positively correlated
with classical CVD risk factors such as age, waist:hip ratio,
blood pressure and carotid intima-media thickness(28). The
PulseTrace equipment calculates SIDVP by recording three
consecutive waveforms through the index finger pulse; SIDVP
is calculated by dividing the subject’s height by the difference
in time between the systolic-derived peak and the diastolic-
derived peak of the waveform. In addition to the replicates
performed by PulseTrace, this technique was performed
three times, giving an average of nine readings at each time
point.
Blood samples were collected every 30 min into K3EDTA or
serum tubes and centrifuged at 48C within 30 min of collection.
For analysis of GIP, 10 ml of dipeptidyl peptidase IV inhibitor
(Millipore Corporation, Watford, Herts, UK) per ml of blood
were added at the time of collection to protect against proteol-
ysis. Samples were stored immediately at 2208C until analysis.
Serum NEFA were quantified using an automated clinical
chemistry analyser (ILAB 600) with kits supplied by Alpha
Laboratories (Eastleigh, Hants, UK). Instrumentation Labora-
tories (Warrington, Ches, UK) supplied kits for the analysis
of serum TAG, glucose and total cholesterol. Serum insulin
was measured using a dissociation-enhanced lanthanide fluor-
escent immunoassay kit (Perkin Elmer Limited, Beaconsfield,
Bucks, UK). Plasma GIP and serum C-peptide were measured
using commercially available colorimetric ELISA kits (Millipore
Corporation, Watford, Herts, UK) as were serum sI-CAM,
plasma PAI-I and ET-1 (R&D Systems Europe Limited,
Abingdon, Oxon, UK). Total serum nitrites (NOx) were
measured using a NO quantification kit (Actif Motif, Rixensart,
Belgium).
In four subjects, fatty acid composition analysis of NEFA and
TAG was performed on baseline fasted samples and those
collected between 300 and 360 min following the start of the
oral fat load. Lipids were extracted from 800ml serum using
chloroform–methanol (2:1, by vol.) containing butylated
hydroxytoluene (50 mg/ml) before being applied to a solid-
phase extraction cartridge (Varian, Oxford, Oxon, UK) to
isolate the NEFA and TAG fractions. These fractions were
then saponified and methylated in methanol containing 2 %
(v/v) H2SO4 at 708C for 1 h. Fatty acid methyl esters were
recovered by extraction into hexane and analysed in a gas
chromatograph as described previously(29). Fatty acid methyl
esters were identified by comparison of retention times against
a known standard, Supelco 37 component fatty acid methyl
esters mix (Supelco, Dorset, UK).
Statistical analysis
All statistical analyses were performed using SPSS software
(version 15.0; SPSS, Inc., Chicago, IL, USA). Data were tested
for normality using the Shapiro–Wilk test and log-transformed
if necessary. Analytes measured at least four times a day
(NEFA, TAG, glucose, insulin, C-peptide and GIP) were com-
pared using repeated-measures ANOVA. This approach was
also used to compare the fatty acid composition of NEFA
and TAG between the study days. Analytes measured only at
0 and 330 min (sI-CAM, NOx, ET-1 and PAI-1) were analysed
with repeated-measures ANCOVA using 330 min as the
dependent variable and 0 min as a covariate. In both cases,
a Bonferroni correction was applied to control for multiple
comparisons. Values of P#0·05 were considered as significant.
Results
Baseline subject characteristics are shown in Table 1. There
were no significant differences in any baseline measures
between the test drinks.
Serum NEFA, TAG and glucose
There was an initial decline in NEFA after consumption of the
bolus oral load followed by a sharp increase at 120 min
following initiation of heparin infusion. The oral fat–heparin
protocol resulted in a threefold elevation of serum NEFA
following consumption of both fats compared with that of
the control (Fig. 1). Repeated-measures ANOVA revealed a
significant effect of test drink and time (P,0·001); both
MUFA- and SFA-rich drinks (P,0·001) elicited a higher NEFA
response than the control, with no significant difference
between the two fats (P¼0·193).
The fatty acid composition of NEFA and TAG at baseline
(t ¼ 0 min) and after consumption of the control, SFA and
MUFA-rich drinks (t ¼ 300–360 min) is shown in Table 2. A
significant effect of test drink was found for palmitic acid
(NEFA and TAG, P,0·001), stearic acid (NEFA only,
P¼0·001), oleic acid (NEFA and TAG, P#0·001) and linoleic
acid (NEFA P¼0·001 and TAG P¼0·020). There was an
approximately 1·5-fold increase in the palmitic acid content
of both NEFA and TAG following consumption of the SFA
test drinks. Consumption of the MUFA test drinks led to an
approximately 2·5-fold increase of oleic acid in NEFA and an
approximately 1·7-fold increase in TAG, which was
accompanied by significant decreases in palmitic acid. Con-
sumption of the control drinks did not affect proportions of
any of the fatty acids from baseline in either NEFA or TAG.
A significant effect of test drink, time and test drink 3 time
interaction (all P,0·001) was found for serum TAG (Fig. 1(b)).
Consumption of both MUFA- and SFA-rich drinks (P,0·001)
was followed by a rise in serum TAG with no rise following
consumption of the control drink. There was an initial decline
in serum TAG following the administration of heparin at
120 min, but thereafter, values remained constant. There was
no significant difference in the serum TAG profiles for the
two test fats (P¼1·000).
Serum glucose levels initially increased at 30 min following
the bolus oral load on all three drinks and then declined to
below-fasting levels until 240 min when there was a steady
increase, most markedly for the two fat test drinks following
heparin infusion (Fig. 2(c)). There was a significant effect of
time (P,0·001) but not of test drink (P¼0·118).
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Serum insulin, C-peptide and gastric inhibitory peptide
response
Serum insulin levels increased following the bolus oral load of
both fats, reaching a peak at 60 min (Fig. 2(a)). There was no
insulin response to consumption of the control drink. Follow-
ing administration of heparin, there was a sharp increase in
insulin for the MUFA-rich drink at 150 min (95 % CI 43·3,
65·3 pmol/l), which was significantly different from the control
at this time point (95 % CI 14·4, 36·9 pmol/l). In contrast, there
was no rise in serum insulin at 150 min for the SFA-rich drink
(95 % CI 27·1, 49 pmol/l). There was a significant effect of test
drink, time and test drink 3 time interaction for overall insulin
response (P,0·001), with both SFA- and MUFA-rich drinks
eliciting a higher insulin response than the control drink
(P,0·001); however, there was no significant difference T
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Fig. 1. Serum (a) NEFA, (b) TAG and (c) glucose (note the broken scale of
the y-axis) during the consumption of SFA ( ), MUFA ( ) or control, no fat
( ). Values are means of ten subjects, with their standard errors represented
by vertical bars; indicates administration of heparin. For serum NEFA
and TAG, repeated-measures ANOVA revealed a significant effect of test
drink (P,0·001), time (P,0·001) and test drink 3 time interaction (NEFA
P¼0·031, TAG P,0·001). For glucose, there was a significant effect of time
only (P,0·001).
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between the fats (P¼1·000). For C-peptide, there was a signifi-
cant effect of test drink (P¼0·010) and time (P,0·001)
(Fig. 2(b)). Compared with the control drink, the response
was significantly higher for the SFA-rich drink (P¼0·013),
with also a strong trend for MUFA values to be higher than
the control (P¼0·056), but there was no difference between
the fats (P¼1·000).
There was a marked increase in plasma GIP following the
consumption of both fat-containing drinks, which was sus-
tained for the duration of the study day (Fig. 2(c)).
Repeated-measures ANOVA revealed a significant effect of
test drink, time and test drink £ time interaction (P,0·001);
both fats induced a higher response than the control
(P,0·001). Despite no statistically significant overall
difference between the fats (P¼0·097), MUFA induced a
significantly higher early response at 90 min (95 % CI 232,
302 pg/ml) than SFA (95 % CI 145, 215 pg/ml).
Markers of endothelial function
Despite the high inter-subject variation in SIDVP during the
study days (Fig. 3), there was a clear increase in this measure
during the consumption of the SFA-rich drink, which peaked
at 210 min. In the case of the MUFA-rich drink, values declined
towards 210 min, increasing slightly at 330 min. Because of
varied baselines between the study days, SIDVP was analysed
by a repeated-measures ANCOVA using mean SIDVP
(90–330 min) as the dependent variable; this revealed a sig-
nificant effect of test drink (P¼0·001). SIDVP was higher
during the consumption of the SFA-rich drink than during
the consumption of the control drink (P,0·001), but there
was no statistical significance between the MUFA-rich and
control drinks (P¼0·089) or the SFA-rich and MUFA drinks
(P¼0·128).
Table 3 shows the effect of test drinks on circulating mar-
kers of endothelial function. There was a significant effect of
test drink on sI-CAM levels (P¼0·014). Pairwise analysis
showed that levels of sI-CAM were significantly higher
during the consumption of the SFA-rich drink than during
the consumption of either the MUFA-rich (P¼0·048) or the
control (P¼0·021) drink, while there was no difference
between the response to MUFA and the control (P¼1·000).
PAI-1 and NOx decreased during the study days, while ET-1
increased (P,0·001), but there was no effect of test drink
compared with the control for any of these parameters.
Discussion
The present study demonstrates that acute elevation of serum
NEFA by the consumption of a SFA-rich drink leads to an
increase in arterial stiffness and levels of sI-CAM in healthy
young men. These effects were not found following ingestion
of a MUFA-rich drink, suggesting that the composition of fat
consumed is an important factor in determining the impact
of elevated NEFA on both vascular function and endothelial
inflammation. The present protocol resulted in a three- to
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Fig. 2. Serum (a) insulin, (b) C-peptide (note the broken scale of the y-axis)
and (c) gastric inhibitory peptide (GIP) during the consumption of SFA ( ),
MUFA ( ) or control, no fat ( ). Values are means of ten, seven and nine
subjects, respectively, with standard errors represented by vertical bars;
indicates administration of heparin. * Denotes a significantly higher
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Fig. 3. Arterial stiffness index during the consumption of SFA ( ), MUFA ( )
or control, no fat ( ) (note the broken scale of the y-axis). Values are means
of eight subjects, with their standard errors represented by vertical bars;
indicates administration of heparin. Repeated-measures ANCOVA of
mean stiffness index derived from digital volume pulse (90–330 min)
revealed a significant effect of test drink (P¼0·001).
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fourfold increase in NEFA from baseline in our healthy
subjects, achieving levels observed in insulin-resistant states
such as obesity and T2D. A subset analysis of fatty acid com-
position of NEFA and TAG also confirmed that the protocol
significantly increased the proportions of palmitic and oleic
acids during the SFA and MUFA study days, respectively.
The present study confirms the findings of published lipid
infusion studies, which have shown that experimental acute
elevation of NEFA impairs vascular function(4,30–36); this is
also reflected in postprandial studies, which have shown simi-
lar adverse effects of all types of high-fat meals(37). However,
unlike the findings of lipid infusion studies, which have
analysed markers of vascular function and inflammation in
response to elevating NEFA rich in n-6 PUFA, the protocol
adopted in the present study has enabled a comparison of
the acute effects of SFA and MUFA. As such, there are no pre-
vious studies to directly compare the present results, although
several postprandial studies have compared the effect of
mixed meals rich in SFA or MUFA on vascular function, with
variable results. Comparison of outcomes from different post-
prandial studies is complicated by virtue of differences in the
amount and source of the fats used in the oral fat load. For
example, shea butter is rich in stearic acid and has been
shown to have varying absorption rates following acute inges-
tion, which would confound data from this type of study(38).
In addition, the amount and type of carbohydrate in test
meals in different studies is also variable which, through dif-
fering effects on insulin secretion, would introduce additional
variables other than the fat type. Raitakari et al.(14) reported
that FMD did not change after a cooked breakfast rich in
SFA or MUFA. Rueda-Clausen et al.(13) also found a similar
reduction in FMD after consumption of potato soup contain-
ing either olive oil or palm oil. In contrast, Berry et al.(15)
found a significant reduction in FMD after a meal of muffins
and a milkshake enriched in high-oleic sunflower oil, which
was not found when the meal was enriched with shea
butter. However, in this latter study, consumption of the
MUFA-rich meal led to significantly higher circulating TAG
levels than consumption of the SFA-rich meal. This could
affect vascular function as the extent of postprandial lipaemia
has been shown to be negatively correlated with FMD in
healthy subjects consuming high-fat meals(39,40). In the present
study, the oils used for the SFA fat load were chosen to reflect
typical UK fatty acid intakes, and, importantly, no difference
was recorded between circulating TAG levels during con-
sumption of either the SFA- or the MUFA-rich fat loads,
suggesting that the observed differences in vascular markers
are due to qualitative rather than quantitative differences in
the raised serum NEFA. Since circulating TAG-rich lipoproteins
have been shown to interact directly with the endothelium,
the possibility that differences in the composition of TAG in
these particles may be responsible for the observed effects
on endothelial function should also be considered.
One mechanism linking fatty acids to vascular function is
the potential effect on insulin secretion, as insulin is an
important mediator of cardiovascular health(41). Consumption
of both fat loads caused a prompt increase in serum insulin
peaking at 60 min, with a concomitant increase in serum
C-peptide. Both saturated and unsaturated NEFA have been
shown to act directly on pancreatic b-cells to acutely increase
insulin secretion in vitro; however, in vivo, the impact of NEFA
on insulin depends on the prevailing glucose concentration,
with a limited effect of NEFA at low glucose concentrations(42).
Although the glucose load in the drinks was minimal, a small
increase in blood glucose concentration was observed at
30 min for all drinks, including the control, which suggests
that the early insulin peak observed for the two fat-containing
drinks reflects glucose-stimulated insulin secretion. Enhanced
insulin secretion at 60 min observed for the fat-containing
drinks, despite similar increases in glucose at 30 min for all
three drinks, illustrates the potentiating effect of oral fatty
acids on glucose-stimulated insulin secretion and influence
of fat ingestion on glucose homeostasis(43). It has long been
known that oral fat is the most potent stimulus to GIP
secretion. In vitro studies have shown that fatty acids can
directly influence the release of GIP from the K-cells of the
intestine, and that GIP binds to specific G-protein-linked
receptors on the surface of the pancreatic b-cells to stimulate
insulin secretion(42). Although the overall GIP responses were
similar for the two fats, there was a higher GIP concentration
at 90 min for the MUFA- v. the SFA-rich fat load, which may
have contributed to the second insulin response at 150 min
for the MUFA fat load, which was not observed for the SFA
fat load. The findings in the present study are consistent
with those of Thomsen et al.(20), who reported a greater
increase in GIP and GLP-1 after consumption of a mixed
Table 3. Circulating markers of endothelial function during the study days
(Mean values with their standard errors, n 10)
SFA MUFA Control
0 min 330 min 0 min 330 min 0 min 330 min
ANCOVA
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM P
sI-CAM (ng/ml) 178 18 184* 20 174 16 168† 16 168 17 166 17 0·014
PAI-1 (ng/ml) 4·7 0·9 2·6 0·56 3·4 0·58 2·2 0·51 4·5 0·97 3·1 0·57 0·346
ET-1 (ng/ml) 1·16 0·06 1·24 0·07 1·22 0·05 1·24 0·07 1·20 0·08 1·20 0·04 0·815
NOx (mM) 13·4 2·1 9·2 1·3 10·9 1·4 8·7 1·1 11·2 1·4 7·1 1·1 0·127
sI-CAM, soluble intercellular cell adhesion molecule-1; PAI-1, plasminogen activator inhibitor-1; ET-1, endothelin-1; NOx, total nitrites.
* Mean value was significantly different from that of control (P,0·05).
† Mean value was significantly different from that of SFA (P,0·05).
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meal containing olive oil v. butter, as well as those of Brynes
et al.(44) who reported a trend towards greater GLP-1 levels
after consumption of olive oil v. butter or maize oil. In con-
trast, Zampelas et al.(45) found no differences in GIP response
after consumption of mixed meals rich in either SFA, n-6 PUFA
or n-3 PUFA. We have no direct evidence to link the more
adverse effect of a SFA- than a MUFA-rich fat load on arterial
stiffness to the differences that we have observed in circulating
incretin or insulin, but the protocol that we have used does
add further support for an acute impact of fatty acid compo-
sition on the entero-insular axis.
Previous studies of the effect of dietary fat on markers of
endothelial dysfunction have produced inconsistent findings.
Nappo et al.(46) found that consumption of a high-fat meal
increased circulating sI-CAM levels, but Dekker et al.(47)
found no effect of a series of high-fat meals varying in their
polyunsaturated:saturated ratio on either sI-CAM or soluble
vascular adhesion molecule-1 levels. The present study
found that acute elevation of NEFA during consumption of a
SFA-rich but not of a MUFA-rich fat load resulted in modestly
increased levels of sI-CAM, a circulating indicator of endo-
thelial inflammation, which has been proposed as a useful
marker of underlying coronary artery disease in healthy sub-
jects(48). Although there are a number of mechanisms whereby
elevation of NEFA may be linked with endothelial inflam-
mation and dysfunction(32,48,49), an increase in sI-CAM may
indicate imbalance in insulin signalling in the endothelium
since stimulation of the mitogen-activated protein kinase path-
way, but not of the phosphoinositide 3-kinase pathway,
results in an increase in the expression of cellular adhesion
molecules, including sI-CAM. This may have a significant
impact on endothelial function, as insulin signalling is a
mediator of vascular tone through the generation of NO via
the phosphoinositide 3-kinase pathway and the vasoconstric-
tor ET-1 via the mitogen-activated protein kinase pathway;
this latter pathway can also lead to the generation of pro-
thrombotic PAI-1(41). However, the present study found no
difference in the response to the different test drinks of circu-
lating markers of endothelium function (ET-1, NOx and PAI-1)
other than the modest increase that we have observed in
sI-CAM. There is therefore insufficient evidence to conclude
that the increase in arterial stiffness reported with the SFA-
rich fat load is related to the impairment of insulin signalling
pathways that regulate NO release or the expression of
these proteins.
The protocol used in the present study achieved a success-
ful threefold elevation of circulating NEFA, comparable with
that found in the study of Beysen et al.(26). Subjects in the pre-
sent study had higher fasting levels of NEFA (average 667
mmol/l) compared with the group of Beysen et al. (260–400
mmol/l), which may have contributed to the higher absolute
NEFA values that we observed following heparin adminis-
tration. A limitation of our sample processing meant that up
to 30 min could have elapsed before samples were stored at
4oC; this could have resulted in a degree of in vitro lipolysis
in the post-heparin samples and may have contributed to
the higher values that we have reported here.
In conclusion, the main finding of the present study is that
an acute elevation of serum NEFA following consumption of a
SFA-rich drink has an adverse impact on arterial stiffness and
sI-CAM levels. The study also confirms that ingestion of a fat
load leads to sustained increases in the incretin hormone
GIP, with some evidence for a more marked effect of MUFA
than for SFA. It is not possible to determine whether the effects
of different fats on vascular tone and endothelial inflammation
are related to differential effects on incretin or insulin
secretion and/or action at the endothelium. However, given
the known effects of NEFA elevation on other insulin-sensitive
tissues such as skeletal muscle and adipose tissue, further
elucidation of the effects of fat type on the sensitivity of the
endothelium to insulin is warranted.
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